top
Search terms
Results 1 - 10 of 16 - ordered by :
Pages: 1 2
Ejhf

Aim We aimed to study the relationships of loop diuretic dose with renal function and clinical outcomes in patients with chronic heart failure (HF). The relationship to change in estimated ...

European Journal of Heart Failure, Damman, Kevin, Kjekshus, John, Wikstrand, John, Cleland, John G.F., Komajda, Michel, Wedel, Hans, Waagstein, Finn, McMurray, John J.V.

Date : 01/03/2016 Item size : 50791 bytes
Ejhf

Introduction Chronic heart failure (HF) is a debilitating condition characterized by progression over time leading to considerable morbidity and mortality. [4] Unlike myocardial infarction (MI) and ...

European Journal of Heart Failure, Kristensen, Søren L., Jhund, Pardeep S., Køber, Lars, Preiss, David, Kjekshus, John, McKelvie, Robert S., Zile, Michael R., Anand, Inder S., Wikstrand, John, ...

Date : 01/02/2015 Item size : 150424 bytes
Ejhf

Introduction Telomeres are repetitive nucleotide sequences located at the extreme ends of chromosomes, which act as protective caps preventing damage to gene-coding information of the DNA. Methods ...

European Journal of Heart Failure, Haver, Vincent G., Mateo Leach, Irene, Kjekshus, John, Fox, Jayne C., Wedel, Hans, Wikstrand, John, de Boer, Rudolf A., van Gilst, Wiek H., McMurray, John J.V., van ...

Date : 01/03/2015 Item size : 178026 bytes
Ejhf

Patients The design and principal findings of CORONA have been reported in detail.11,12 Patients aged ≥60 years with chronic New York Heart Association (NYHA) class II-IV HF of ...

European Journal of Heart Failure, Inglis, Sally C., McMurray, John J.V., Böhm, Michael, Schaufelberger, Maria, Veldhuisen, Dirk J., Lindberg, Magnus, Dunselman, Peter, Hjalmarson, Åke, Kjekshus, ...

Date : 01/07/2010 Item size : 188376 bytes
Ejhf

Executive Committee: P.D., Amphia Hospital, Breda, Netherlands; A.H., Dept. of Cardiology, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden (Chairman of the Executive ...

European Journal of Heart Failure, Lorgelly, Paula K., Briggs, Andrew H., Wedel, Hans, Dunselman, Peter, Hjalmarson, Åke, Kjekshus, John, Waagstein, Finn, Wikstrand, John, Jánosi, András, ...

Date : 01/01/2010 Item size : 166536 bytes
Ejhf

Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive ...

European Journal of Heart Failure, Wedel, Hans, McMurray, John J.V., Lindberg, Magnus, Wikstrand, John, Cleland, John G.F., Cornel, Jan H., Dunselman, Peter, Hjalmarson, Åke, Kjekshus, John, ...

Date : 01/03/2009 Item size : 233317 bytes
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012 Item size : 369253 bytes
Ehjournal

Compared with Group A, Group C had a higher risk of non-fatal myocardial infarction or unstable angina (HR: 2.36, 1.543.61; P < 0.001), this composite plus coronary revascularization (HR: 2.54, ...

European Heart Journal, Badar, Athar A., Perez-Moreno, Ana Cristina, Jhund, Pardeep S., Wong, Chih M., Hawkins, Nathaniel M., Cleland, John G.F., van Veldhuisen, Dirk J., Wikstrand, John, Kjekshus, ...

Date : 21/12/2014
Ehjournal

Compared with Group A, Group C had a higher risk of non-fatal myocardial infarction or unstable angina (HR: 2.36, 1.543.61; P < 0.001), this composite plus coronary revascularization (HR: 2.54, ...

European Heart Journal, Badar, Athar A., Perez-Moreno, Ana Cristina, Jhund, Pardeep S., Wong, Chih M., Hawkins, Nathaniel M., Cleland, John G.F., van Veldhuisen, Dirk J., Wikstrand, John, Kjekshus, ...

Date : 21/12/2014
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012